Abstract
A 65-year-old woman with a gastrointestinal stromal tumor(GIST)underwent a total gastrectomy in 1999. In 2004, she was diagnosed with an intra-abdominal recurrence and was treated with 300mg/day of imatinib. Because of the side effects of imatinib, we interrupted the treatment and were forced to reduce the dose from 300mg/day to 100mg/day. However, at present, the tumor remains controlled. In conclusion, this case suggested that, even if given irregularly or at a low-dose, continuous treatment with imatinib might contribute to long-term survival in patients with GIST.
Publication types
-
Case Reports
-
English Abstract
-
Review
MeSH terms
-
Aged
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use*
-
Benzamides / administration & dosage
-
Benzamides / therapeutic use*
-
Female
-
Gastrointestinal Stromal Tumors / drug therapy*
-
Gastrointestinal Stromal Tumors / surgery
-
Humans
-
Imatinib Mesylate
-
Piperazines / administration & dosage
-
Piperazines / therapeutic use*
-
Pyrimidines / administration & dosage
-
Pyrimidines / therapeutic use*
-
Recurrence
-
Stomach Neoplasms / drug therapy*
-
Stomach Neoplasms / pathology
-
Stomach Neoplasms / surgery
-
Time Factors
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Pyrimidines
-
Imatinib Mesylate